Trial Profile
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3 and AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 or CNGA3
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2022
Price :
$35
*
At a glance
- Drugs Entacingene turiparvovec (Primary)
- Indications Colour vision defects
- Focus Adverse reactions
- Sponsors MeiraGTx
- 13 Jan 2022 Planned End Date changed from 7 Aug 2024 to 15 Jan 2026.
- 13 Jan 2022 Planned primary completion date changed from 10 Jul 2024 to 15 Jan 2026.
- 13 Jan 2022 Status changed from recruiting to active, no longer recruiting.